NRIX Nurix Therapeutics Inc
Price (delayed)
$25.54
Market cap
$1.65B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.92
Enterprise value
$1.56B
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer
Highlights
NRIX's equity has surged by 120% since the previous quarter and by 43% year-on-year
NRIX's quick ratio has surged by 97% since the previous quarter and by 41% year-on-year
NRIX's gross profit is down by 23% from the previous quarter but it is up by 2.2% YoY
The revenue has contracted by 23% from the previous quarter but it has grown by 2.2% YoY
The net income has declined by 14% since the previous quarter and by 4.8% year-on-year
NRIX's EPS is down by 10% since the previous quarter
Key stats
What are the main financial stats of NRIX
Market
Valuations
Earnings
Shares outstanding
64.41M
Market cap
$1.65B
Enterprise value
$1.56B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.39
Price to sales (P/S)
25.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.98
Revenue
$62.3M
EBIT
-$164.82M
EBITDA
-$149.7M
Free cash flow
-$105.97M
Per share
Balance sheet
Liquidity
EPS
-$2.92
Free cash flow per share
-$1.7
Book value per share
$7.54
Revenue per share
$1
TBVPS
$8.19
Total assets
$511.03M
Total liabilities
$140.34M
Debt
$28.82M
Equity
$370.69M
Working capital
$369.44M
Debt to equity
0.08
Current ratio
5.57
Quick ratio
5.5
Net debt/EBITDA
0.59
Margins
Efficiency
Dividend
EBITDA margin
-240.3%
Gross margin
100%
Net margin
-264.8%
Operating margin
-287.5%
Return on assets
-44.4%
Return on equity
-67.8%
Return on invested capital
-65.9%
Return on capital employed
-38.3%
Return on sales
-264.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NRIX stock price
How has the Nurix Therapeutics stock price performed over time
Intraday
2.86%
1 week
7.45%
1 month
14.63%
1 year
186.64%
YTD
147.48%
QTD
22.38%
Financial performance
How have Nurix Therapeutics's revenue and profit performed over time
Revenue
$62.3M
Gross profit
$62.3M
Operating income
-$179.11M
Net income
-$165M
Gross margin
100%
Net margin
-264.8%
Nurix Therapeutics's operating margin has decreased by 48% QoQ and by 6% YoY
NRIX's net margin is down by 48% since the previous quarter and by 2.5% year-on-year
NRIX's gross profit is down by 23% from the previous quarter but it is up by 2.2% YoY
The revenue has contracted by 23% from the previous quarter but it has grown by 2.2% YoY
Growth
What is Nurix Therapeutics's growth rate over time
Valuation
What is Nurix Therapeutics stock price valuation
P/E
N/A
P/B
3.39
P/S
25.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.98
NRIX's EPS is down by 10% since the previous quarter
NRIX's equity has surged by 120% since the previous quarter and by 43% year-on-year
The stock's price to book (P/B) is 50% more than its last 4 quarters average of 2.2 and 18% more than its 5-year quarterly average of 2.8
The stock's price to sales (P/S) is 183% more than its last 4 quarters average of 8.8 but 2.1% less than its 5-year quarterly average of 25.4
The revenue has contracted by 23% from the previous quarter but it has grown by 2.2% YoY
Efficiency
How efficient is Nurix Therapeutics business performance
NRIX's return on sales is down by 48% since the previous quarter and by 2.4% year-on-year
The ROE has contracted by 27% YoY
NRIX's return on invested capital is down by 21% year-on-year
NRIX's return on assets is down by 13% year-on-year
Dividends
What is NRIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NRIX.
Financial health
How did Nurix Therapeutics financials performed over time
NRIX's quick ratio has surged by 97% since the previous quarter and by 41% year-on-year
NRIX's current ratio has surged by 95% since the previous quarter and by 39% year-on-year
NRIX's debt is 92% smaller than its equity
NRIX's equity has surged by 120% since the previous quarter and by 43% year-on-year
The debt to equity has surged by 100% year-on-year but it has dropped by 53% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.